Endotoxin in Gram-negative Septic Shock

This study is currently recruiting participants.
Verified June 2012 by Azienda Ospedaliero, Universitaria Pisana
Sponsor:
Information provided by (Responsible Party):
Imma Tatiana Borrelli, Azienda Ospedaliero, Universitaria Pisana
ClinicalTrials.gov Identifier:
NCT01602354
First received: May 17, 2012
Last updated: June 27, 2012
Last verified: June 2012

May 17, 2012
June 27, 2012
April 2012
June 2013   (final data collection date for primary outcome measure)
  • Level of Endotoxin in blood samples [ Time Frame: admission date (baseline) ] [ Designated as safety issue: No ]
    Values of endotoxin are also compared to SOFA, SAPSII, PLT, WBC
  • Change of Endotoxin from baseline [ Time Frame: 3 days after admission ] [ Designated as safety issue: No ]
    Values of endotoxin are also compared to SOFA, SAPSII, PLT, WBC
  • Change of Endotoxin from baseline [ Time Frame: 7 dayf after admission ] [ Designated as safety issue: No ]
    Values of endotoxin are also compared to SOFA, SAPSII, PLT, WBC
Same as current
Complete list of historical versions of study NCT01602354 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Endotoxin in Gram-negative Septic Shock
Endotoxin Activity Assay as a Prognostic Factor in Gram-negative Septic Shock

The purpose of this observational study is to determine whether endotoxin levels and/or their trends can be considered predictive of morbility or mortality in septic shock caused by gram-negative bacteria, searching also for a possible correlation with Simplified Acute Physiology Score (SAPS II), Sequential Organ Failure Assessment (SOFA), White Blood Cells (WBC) and Platelets (PLT).

Medical literature states that Endotoxin (a structural molecule of the Gram-negative bacteria extracellular membrane) is able to activate target cells such as macrophages and neutrophils, inducing them to produce and release cytokine, nitric oxide and other mediators that cause a systemic inflammatory response that can evolve until to endothelial damage, shock and multi-organ failure (MOF).

Since 2004 it has been possible to better determine the concentration and the activity of endotoxin in plasma, thanks to a reliable and quick to implement method: the EAA (Endotoxin Activity Assay) test, which is an alternative technique for detecting endotoxin in whole blood based on the detection of enhanced respiratory burst activity in neutrophils following their priming by complexes of endotoxin and a specific anti-endotoxin antibody. The EAA shows excellent performance characteristics in recovering endotoxin from spiked samples and can be performed within 30 min, using less than 100µl whole blood.

Participants of this study (all affected by gram-negative septic shock) will show different values of endotoxin in their blood samples during their stay in Intensive Care Unit (ICU), and the investigators will try to figure out if these values and their trends can be somehow predictive of morbility and/or mortality, despite the small number of septic patients and the heterogeneity of their clinical picture.

So, if endotoxin induces sepsis, can the investigators also state that high values and/or trends of endotoxin can be correlated to severity of disease?

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

whole blood

Probability Sample

Patients admitted to Intensive Care Unit with a diagnosis of severe sepsis or septic shock

Gram Negative Septic Shock
Not Provided
Gram-negative Septic shock
Patients affected by Gram-negative septic shock
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
July 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • diagnosis of severe sepsis or septic shock
  • acquisition of informed consent
  • age over 18 years old

Exclusion Criteria:

  • any diagnosis different from severe sepsis or septic shock
  • rejection of informed consent by participant
  • age under 18 years old
  • any clinic condition considered not suitable by researcher
Both
18 Years and older
No
Not Provided
Italy
 
NCT01602354
EAA G- SEP
No
Imma Tatiana Borrelli, Azienda Ospedaliero, Universitaria Pisana
Azienda Ospedaliero, Universitaria Pisana
Not Provided
Study Director: Francesco Forfori, Researcher Department of Intensive Care Unit, Azienda Ospedaliero-Universitaria (AOU) Pisana
Study Chair: Francesco Giunta, Professor Depatment of Intensive Care Unit, AOU Pisana
Principal Investigator: Imma Tatiana Borrelli, Doctor Department of Intensive Care Unit, AOU Pisana
Azienda Ospedaliero, Universitaria Pisana
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP